BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30165102)

  • 1. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
    Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
    Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.
    Stricker HM; Rommerswinkel N; Keil S; Gnoth SA; Niggemann B; Dittmar T
    Cell Commun Signal; 2021 Apr; 19(1):43. PubMed ID: 33832505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
    Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
    Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
    Campiglio M; Ali S; Knyazev PG; Ullrich A
    J Cell Biochem; 1999 Jun; 73(4):522-32. PubMed ID: 10733345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
    Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH
    FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG; Hosick HL; Ethier SP
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential signaling by an anti-p185(HER2) antibody and heregulin.
    Le XF; Vadlamudi R; McWatters A; Bae DS; Mills GB; Kumar R; Bast RC
    Cancer Res; 2000 Jul; 60(13):3522-31. PubMed ID: 10910064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
    Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
    Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role for the catalytic activity of phospholipase C-gamma1 in epidermal growth factor-induced cell migration.
    Xie Z; Peng J; Pennypacker SD; Chen Y
    Biochem Biophys Res Commun; 2010 Aug; 399(3):425-8. PubMed ID: 20674545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
    Adelsman MA; McCarthy JB; Shimizu Y
    Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family.
    Schelfhout VR; Coene ED; Delaey B; Thys S; Page DL; De Potter CR
    J Natl Cancer Inst; 2000 Apr; 92(8):622-8. PubMed ID: 10772679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.